Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Averin Capital Acquisition Corp.ACAAU · Entity 5761 | Director | May 28, 2026 | May 29, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | May 01, 2025 | May 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Averin Capital Acquisition Corp.
Report date May 28, 2026 · Filed May 29, 2026
This filing explicitly reported no securities owned.
HALOZYME THERAPEUTICS, INC.
Report date May 01, 2025 · Filed May 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,937 |
Reported balance
After 2025-05-01 transaction · row 1
1 source rowRow 1 · 2025-05-01 · Grant · Acquired 4,165 · Balance 24,937 F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $60.03 · Expires 2035-05-01 | Direct | 5,750 |
Reported balance
After 2025-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-01 · Grant · Acquired 5,750 · Balance 5,750 F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 2, 2025 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 5,750 | $0.00 Strike: $60.03 | $0.00 |
DisclosureSEC source: 0001415889-25-011776 · form4-05022025_080541.xml · derivative · entry 2 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-05-01 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 4,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011776 · form4-05022025_080541.xml · nonDerivative · entry 1 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,937 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 8,804 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001415889-24-011701 · form4-04292024_100402.xml · derivative · entry 2 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 6,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011701 · form4-04292024_100402.xml · nonDerivative · entry 1 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,772 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007693 · form4-05092023_100556.xml · derivative · entry 2 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007693 · form4-05092023_100556.xml · nonDerivative · entry 1 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,271 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2022 Filed May 7, 2022 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 6,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002911 · edgar.xml · nonDerivative · entry 1 Miyashita Akiko Moni · CIK 0001607742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,206 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.